Anagliptin
A DPP-4 inhibitor that prevents the breakdown of hormones called incretins, which stimulate insulin release after eating, helping to lower blood sugar in type 2 diabetes. It is used as part of a comprehensive diabetes management plan.
Masse moléculaire
383,4000 g/mol
LogP
0,00
TPSA
115,00 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Structure 2D
Cite this structure
Embed this structure
SMILES
Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1
InChI
InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1
Molecular Formula
C19H25N7O2
HBD / HBA
2 / 6
Liaisons Rotatives
6
Atomes Lourds
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A DPP-4 inhibitor that prevents the breakdown of hormones called incretins, which stimulate insulin release after eating, helping to lower blood sugar in type 2 diabetes. It is used as part of a comprehensive diabetes management plan.
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Yes, Anagliptin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1929396. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 44513473. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="anagliptin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/anagliptin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/anagliptin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/anagliptin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="anagliptin"></drugfyi-drug>